Literature DB >> 21568692

Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways.

Shin Hirayama1, Masaaki Sato, Mingyao Liu, Severine Loisel-Meyer, Jonathan C Yeung, Dirk Wagnetz, Marcelo Cypel, Guan Zehong, Jeffrey A Medin, Shaf Keshavjee.   

Abstract

Obliterative bronchiolitis (OB) is a form of chronic rejection after lung transplantation. Lentiviral vectors (LVs) facilitate long-term gene transduction in many tissues and organs. We hypothesized that lentiviral gene transfer of interleukin (IL)-10, a potent immune-modulating cytokine, to the lung could modulate the alloimmune responses in the lung after transplantation. C57BL6 mice received LVs encoding luciferase, enhanced green fluorescent protein (eGFP), or human IL-10 (huIL-10) through airways and underwent repeated bioluminescent imaging, immunofluorescence imaging, or ELISA of lung tissues, respectively. Luciferase activities peaked at day 7 and were stable after day 28 to over 15 months. eGFP staining demonstrated LV-mediated gene transduction mainly in alveolar macrophages. LV-huIL-10 delivery resulted in stable long-term expression of huIL-10 in the lung tissue (average 3.66 pg/mg at 1 year). Intrapulmonary allograft tracheal transplantation (BALBc→C57BL6) was used as a model of OB. LV-huIL-10 or LV-eGFP were delivered 7 days before transplantation and compared with no LV-transfection group. Allograft airways at day 28 were almost completely obliterated in all the groups. However, at day 42, allograft airways treated with LV-huIL-10 showed a spectrum of attenuation in airway fibrosis ranging from complete obliteration through bubble-like partial opening to complete patency with epithelial coverage in association with a significantly reduced obliteration ratio compared with the other groups (p<0.05). In conclusion, lentivirus-mediated gene transduction is useful in achieving long-term transgene expression in the lung. Long-term IL-10 expression has the potential to attenuate allograft airway obliteration. LV-mediated gene therapy could be a useful strategy to prevent or treat OB after lung transplantation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21568692     DOI: 10.1089/hum.2010.225

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  7 in total

1.  Zbtb7a induction in alveolar macrophages is implicated in anti-HLA-mediated lung allograft rejection.

Authors:  Deepak K Nayak; Fangyu Zhou; Min Xu; Jing Huang; Moriya Tsuji; Jinsheng Yu; Ramsey Hachem; Andrew E Gelman; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar
Journal:  Sci Transl Med       Date:  2017-07-12       Impact factor: 17.956

Review 2.  Primary graft dysfunction: pathophysiology to guide new preventive therapies.

Authors:  Ciara M Shaver; Lorraine B Ware
Journal:  Expert Rev Respir Med       Date:  2017-01-20       Impact factor: 3.772

Review 3.  Gene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?

Authors:  Qimeng Gao; Isabel F DeLaura; Imran J Anwar; Samuel J Kesseli; Riley Kahan; Nader Abraham; Aravind Asokan; Andrew S Barbas; Matthew G Hartwig
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

4.  High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors.

Authors:  Manij Patel; Angela M Giddings; John Sechelski; John C Olsen
Journal:  J Gene Med       Date:  2013-01       Impact factor: 4.565

5.  A physiologic and biochemical profile of clinically rejected lungs on a normothermic ex vivo lung perfusion platform.

Authors:  Timothy J George; George J Arnaoutakis; Claude A Beaty; Simran K Jandu; Lakshmi Santhanam; Dan E Berkowitz; Ashish S Shah
Journal:  J Surg Res       Date:  2012-11-27       Impact factor: 2.192

Review 6.  Transplantation of Hearts Donated after Circulatory Death.

Authors:  Christopher W White; Simon J Messer; Stephen R Large; Jennifer Conway; Daniel H Kim; Demetrios J Kutsogiannis; Jayan Nagendran; Darren H Freed
Journal:  Front Cardiovasc Med       Date:  2018-02-13

7.  Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy.

Authors:  Uta Griesenbach; Makoto Inoue; Cuixiang Meng; Raymond Farley; Mario Chan; Nikki K Newman; Andrea Brum; Jun You; Angela Kerton; Amelia Shoemark; A Christopher Boyd; Jane C Davies; Tracy E Higgins; Deborah R Gill; Stephen C Hyde; J Alastair Innes; David J Porteous; Mamoru Hasegawa; Eric W F W Alton
Journal:  Am J Respir Crit Care Med       Date:  2012-09-06       Impact factor: 21.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.